<DOC>
	<DOCNO>NCT02302066</DOCNO>
	<brief_summary>The purpose study assess humoral immune response Takeda 's Tetravalent Dengue Vaccine Candidate ( TDV ) administer subcutaneously subset healthy participant 2 &lt; 18 year age living dengue endemic country .</brief_summary>
	<brief_title>Safety Immunogenicity Different Schedules Takeda 's Tetravalent Dengue Vaccine Candidate ( TDV ) Healthy Participants</brief_title>
	<detailed_description>The vaccine test study Takeda 's Tetravalent Dengue Vaccine Candidate ( TDV ) . TDV test assess different dose schedule vaccine effect immunity dengue fever dengue endemic country . This study look number antibody dengue fever form people administer different dosing schedule TDV . The study randomize approximately 1800 patient . Participants randomly assign one four treatment group 1:2:5:1 ratio—which remain undisclosed patient study doctor study ( unless urgent medical need ) : - Group 1 - TDV 0.5 mL subcutaneous ( SC ) injection Days 1 91 - Group 2 - TDV 0.5 mL SC injection Day 1 - Group 3 - TDV 0.5 mL SC injection Days 1 365 - Placebo ( dummy SC ) - liquid look like study drug active ingredient In order keep treatment arm undisclosed patient doctor , participant receive placebo injection study visit TDV administer ( Days 91 and/or 365 ) . Participants ask record symptom may relate vaccine injection site diary card 28 day vaccination . This multi-centre trial conduct Asia Latin America . The overall time participate study 18 month . Participants make 7 visit clinic include final visit 6 month last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Is age 2 &lt; 18 year , time enrollment 2 . Is good health time entry trial determine medical history , physical examination ( include vital sign ) , clinical judgment investigator . 3 . The participant , applicable , participant 's legally acceptable representative sign date write , informed consent form ( assent form , require ) require privacy authorization prior initiation trial procedure , nature trial explain accord local regulatory requirement . 4 . Can comply trial procedure available duration followup . 1 . Febrile illness ( temperature ≥ 38°C 100.4°F ) moderate severe acute illness infection time enrollment . Trial entry delay illness improve . 2 . Individuals history illness , opinion investigator , might interfere result trial pose additional risk participant due participation trial , include limited : . Known hypersensitivity allergy vaccine component ; b . Female participant pregnant breastfeeding ; c. Individuals serious chronic progressive disease accord judgment investigator ( e.g . neoplasm , insulindependent diabetes , cardiac , renal hepatic disease , neurologic seizure disorder GuillainBarré syndrome ) ; d. Known suspect impairment/alteration immune function , include : . Chronic use oral steroid ( Equivalent 20 mg/day prednisone ≥ 12 week / ≥ 2 mg/kg body weight / day prednisone ≥ 2 week ) within 60 day prior Day 1 ( use inhale , intranasal , topical corticosteroid allow ) ; ii . Receipt parenteral steroid ( Equivalent 20 mg/day prednisone ≥ 12 week / ≥ 2 mg/kg body weight / day prednisone ≥ 2 week ) within 60 day prior Day 1 ; iii . Administration immunoglobulins and/or blood product within three month precede first administration investigational vaccine plan administration trial ; iv . Receipt immunostimulants within 60 day prior Day 1 ; v. Immunosuppressive therapy anticancer chemotherapy radiation therapy within 6 month precede ( first ) vaccination ; vi . Human immunodeficiency virus ( HIV ) infection HIVrelated disease ; vii . Genetic immunodeficiency . 3 . Individuals receive vaccine within 14 day ( inactivated vaccine ) 28 day ( live vaccine ) prior enrollment trial planning receive vaccine within 28 day investigational vaccine administration . 4 . Individuals participate clinical trial another investigational product 30 day prior first trial visit intent participate another clinical trial time conduct trial . 5 . Individuals first degree relative individual involve trial conduct . 6 . If female childbearing potential , sexually active , use `` acceptable contraceptive method '' least 2 month prior trial entry : . Of childbearing potential defined status post onset menarche meeting follow condition : menopausal ( least 2 year ) , bilateral tubal ligation ( least 1 year previously ) , bilateral oophorectomy ( least 1 year previously ) hysterectomy ; b . Acceptable birth control method define one following : i. Hormonal contraceptive ( oral , injection , transdermal patch , implant , cervical ring ) ; ii . Barrier ( condom spermicide diaphragm spermicide ) every time intercourse ; iii . Intrauterine device ( IUD ) ; iv . Monogamous relationship vasectomize partner . Partner must vasectomize least six month prior participant ' trial entry . 7 . If female childbearing potential , sexually active refuse use `` acceptable contraceptive method '' 6 week last dose investigational vaccine . 8 . Individuals participate previous dengue vaccine trial .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>